Impact of Sugammadex vs. Neostigmine Reversal on Post-Operative Recovery and Complications

• Status: Recruiting
• Trial end date: 2022-01-31
• Target enrollment: 0
• Participant gender: All

Summary

Sugammadex or neostigmine are given at the end of the surgery to reverse neuro muscular blocking drugs. This study will evaluate whether reversal of NMBD with sugammadex is associated with faster recovery than neostigmine resulting in faster discharge from the operating room (OR) in obese patients with OSA undergoing bariatric surgery. Half of the patients in the study will receive sugammadex and the other half of the patients will receive neostigmine.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Collaborator: Merck Canada Inc.
• Treatments: Neostigmine

Criteria

Inclusion Criteria:

• Age ≥ 18 years old

• Diagnosed Obstructive Sleep Apnea patients by polysomnography

• Scheduled elective bariatric surgery

Exclusion Criteria:

• Age<18 years old

• Allergy to rocuronium

• Allergy to sugammadex

• Allergy to neostigmine

• Malignant hyperthermia

• Hepatic insufficiency

• Renal insufficiency

• Neuromuscular Disease

• Pregnancy